SEATTLE, April 3, 2017 /PRNewswire/ -- Sound Pharmaceuticals, a private biopharmaceutical company, and leader in developing novel drug treatments for the inner ear and brain, announced today that Jonathan Kil, MD, Co-Founder, Chief Executive Officer, and Chief Medical Officer has been invited to present at the 16th Annual Needham & Company Healthcare Conference on Tuesday, April 4th at 1:40 pm EDT in New York, NY.
Dr. Kil will provide an update on the Company's R&D milestone achievements from the past year, along with the strategic objectives for its three neurotologic programs. SPI has four active Investigational New Drug applications with the FDA involving several indications including noise induced hearing loss, Meniere's disease, and chemotherapy and antibiotic induced ototoxicity. In addition, he will highlight some of the significant market opportunities within the field of hearing and balance, specifically, in the area of neurotology.
Needham & Company's 16th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors.
About Sound Pharmaceuticals
Sound Pharmaceuticals, Inc. (SPI) is a pioneer in neurotologic drug development aimed at treating sensorineural diseases of the inner ear. SPI is developing the first therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss and tinnitus including ototoxicity and Meniere's disease. Sensorineural hearing loss is the third largest disease and affects 50 million Americans. SPI is a privately held biotechnology company headquartered in Seattle, WA.
Contact:
Sound Pharmaceuticals[email protected]www.soundpharma.com
Advertisement
Dr. Kil will provide an update on the Company's R&D milestone achievements from the past year, along with the strategic objectives for its three neurotologic programs. SPI has four active Investigational New Drug applications with the FDA involving several indications including noise induced hearing loss, Meniere's disease, and chemotherapy and antibiotic induced ototoxicity. In addition, he will highlight some of the significant market opportunities within the field of hearing and balance, specifically, in the area of neurotology.
Advertisement
Needham & Company's 16th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors.
About Sound Pharmaceuticals
Sound Pharmaceuticals, Inc. (SPI) is a pioneer in neurotologic drug development aimed at treating sensorineural diseases of the inner ear. SPI is developing the first therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss and tinnitus including ototoxicity and Meniere's disease. Sensorineural hearing loss is the third largest disease and affects 50 million Americans. SPI is a privately held biotechnology company headquartered in Seattle, WA.
Contact:
Sound Pharmaceuticals[email protected]www.soundpharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sound-pharmaceuticals-invited-to-present-at-the-16th-annual-needham--company-healthcare-conference-300432325.html
SOURCE Sound Pharmaceuticals
